SCHEMBL3004102

SCHEMBL3004102

Cc1ccccc1Cc1csc(N2CCN(S(=O)(=O)c3cc(Cl)ccc3Cl)CC2)n1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.44
ALDH1A1 P00352 4/20 0.44
TSHR P16473 2/20 0.43
ALOX15 P16050 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
ALDH3A1 P30838 1/20 0.42
USP2 O75604 1/20 0.41
LMNA P02545 4/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
MAPK1 P28482 1/20 0.41
RECQL P46063 1/20 0.41
TP53 P04637 1/20 0.41
NPSR1 Q6W5P4 2/20 0.40
KDM2B Q8NHM5 1/20 0.40
SMN1; SMN2 Q16637 2/20 0.39
KDM4E B2RXH2 1/20 0.39
POLB P06746 1/20 0.39
CNR1 P21554 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3015352 0.93 MAPT (0.43) MAPTALDH1A1TSHRALOX15L3MBTL1
SCHEMBL3009039 0.92 TRPV4 (0.47) MAPTALDH1A1LMNAMEN1KMT2A
SCHEMBL3014221 0.91 CHRM4 (0.44) MAPTALDH1A1LMNAMEN1KMT2A
SCHEMBL3008522 0.90 LMNA (0.44) MAPTALDH1A1LMNAMEN1KMT2A
SCHEMBL3002429 0.90 MAPT (0.44) MAPTALDH1A1TSHRALOX15L3MBTL1
SCHEMBL3002552 0.90 ALDH1A1 (0.50) MAPTALDH1A1TSHRL3MBTL1USP2
SCHEMBL3014116 0.90 MAPT (0.44) MAPTALDH1A1TSHRALOX15L3MBTL1
SCHEMBL3007165 0.89 RAB9A (0.49) MAPTALDH1A1TSHRL3MBTL1LMNA
SCHEMBL3014184 0.88 RECQL (0.38) MAPTALDH1A1TSHRALOX15L3MBTL1
SCHEMBL3011166 0.88 MAPT (0.47) MAPTALDH1A1TSHRL3MBTL1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MAPT 18/4885ALDH1A1 3510/4885TSHR 3320/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.